Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Annual Review of Addiction Medicine Highest Impact Publications (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about Addiction Medicine's highest impact, peer-reviewed journal articles across the field of Addiction Medicine from 2017-2018, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about, and focus on his focus on the annual review of the highest impact, peer-reviewed articles across the field of Addiction Medicine for 2017-2018. The review is composed of brief journal club presentations of each article, organized under the ASAM Principles of Addiction Medicine textbook chapter headings: neurobiology, epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, harm reduction, criminal justice, dual diagnoses, and pharmacologic and behavioral interventions. 

    The goal of this session is to provide the learner with a concise, structured, critical summary of the important recently published scientific papers. All of the core Principles chapters are covered, using the highest rated articles within these topics. Articles are selected by relevance to the topic outline, publication metrics (journal impact factor, most downloaded, Altmetric rankings), and expert opinion. Example articles: Buprenorphine for neonatal abstinence syndrome (Kraft 2017); Opioid prescribing in the ED and long-term use (Barnett 2017); Global prevalence of alcohol use during pregnancy and fetal alcohol syndrome (Popova 2017); Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial (Watkins 2017); Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder (Walsh 2017).

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    Joshua Lee

    MD, MSc

    Joshua D. Lee MD, MSc is an Associate Professor in the Department of Population Health and the Division of General Internal Medicine and Clinical Innovation at the NYU School of Medicine. He directs the NYU Fellowship in Addiction Medicine. His research focuses on medication treatments for addiction among criminal justice and primary care populations.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Leveraging Technologies and EHR in SUD Treatment: NIDA CTN Research Initiatives (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to implement evidence-based practices in the management of substance use disorders, especially opioid use disorders, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that providers at general medical settings are well positioned to identify substance misuse and substance use disorders (SUD). However, implementation challenges have interfered with the adoption of evidence-based practices in the management of SUDs, especially opioid use disorders (OUD). 

    The National Institute on Drug Abuse's National Drug Treatment Clinical Trials Network (CTN) has conducted focused and iterative implementation research to explore the capabilities of electronic health records (EHR) for integrating care, leveraging mobile and other technologies, and sought the input of providers/administrators to increase the adoption of SUD care in general healthcare settings. This workshop will provide an overview of current research projects within the NIDA's CTN that seek to explore EHR tools and leverage technology for better integration of substance use screening and treatment in medical settings; and then engage attendees in a lively discussion of the rationale, study design/methodology and preliminary findings of several implementation science initiatives. The first component consists of brief presentations, while the second consists of interactive discussions between workshop facilitators to elicit valuable feedback and experience narratives from the clinician and research experts in the audience, to better inform ongoing and future research in these areas. 

    Dr. Jennifer McNeely will:

    • summarize validation results of the electronic screen/brief assessment TAPS Tool; 
    • describe an ongoing study to explore the implementation of addiction screening and assessment common data elements (CDEs) into a widely used EHR; and 
    • assess the impact on the management of SUD in multiple health systems. 

    Dr. Gavin Bart will:

    • describe an ongoing pilot clinical decision support (CDS) for the identification and management of OUD in general medical settings in a large EHR system; and 
    • review study objectives of feasibility, usability, and acceptability of the electronic CDS with buprenorphine prescribers. 
    • address pertinent confidentiality and privacy regulations that may be encountered in implementation. 

    Dr. Lisa Marsch will:

    • highlight select research findings leveraging mobile and web-based technologies, including the Therapeutic Education System (TES) intervention in augmenting SUD treatment at specialty care settings and medical settings.

    Geetha A. Subramaniam

    MD, DFAPA, DFAACAP

    Geetha is the Deputy Director of the NIDA Center for Clinical Trials Network. She is a accomplished SUD clinician and researacher. In addition to serving as a collaborative scientist on multi-site clinicat trials, she also is focused on forging alliances with medical organizations like ASAM to help inform physicians and allied health professionals by disseminating emerging research information.

    Jennifer McNeely

    MD, MS

    Jennifer McNeely, MD, MS is Associate Professor at the NYU School of Medicine in the Department of Population Health and Department of Medicine, Division of General Internal Medicine. Dr. McNeely is a general internist specialized in Addiction Medicine, and currently practices at Bellevue Hospital. Her research focuses on improving the identification and treatment of substance use disorders in medical settings, and includes developing screening tools and studying their implementation in primary care.

    Gavin Bart

    MD, PhD, FACP, DFASAM

    Dr. Gavin Bart is Director of the Division of Addiction Medicine at Hennepin County Medical Center and Associate Professor of Medicine at the University of Minnesota. He received his MD from the University of Minnesota and trained in internal medicine at the Hennepin County Medical Center. His PhD is in experimental and clinical pharmacology, also from the University of Minnesota. He trained in addiction medicine at The Rockefeller University where he continued as Director of Clinical Research until moving to Minnesota where is is co-PI of the NorthStar Node of the NIDA Clinical Trials Network. His areas of expertise include clinical pharmacology and the pharmacological management of opioid dependence. 

    His current research areas include the population pharmacokinetics of methadone, genetic influences of methadone pharmacology and treatment outcome, electronic health record privacy provisions of 42 CFR Part 2, and clinical decision support tool development for SUD. 

    He is Chair of the Life-Long Learning and Self-Assessment committee for the American Board of Addiction Medicine and is ASAM Region VI (IA, IL, IN, MI, MN, WI) director. Internationally, he is co-director of the SAMHSA-funded Vietnam HIV and Addiction Technology Transfer Center and provides ongoing technical assistance for the Substance Abuse and Mental Health Administration in South East and Central Asia.

    Lisa Marsch

    PhD

    Lisa A. Marsch, PhD is the Director of the Center for Technology and Behavioral Health (a NIDA-funded P30 Center of Excellence) at Dartmouth College. With funding from NIH, she has led a line of research focused on the development and evaluation of cutting-edge, technology-based (mobile and Internet-delivered) interventions focused on substance abuse treatment among youth and adults, HIV prevention among substance-using youth and adults, substance abuse prevention among children and adolescents, as well as other behavioral health issues. 

    These technology-based therapeutic tools reflect an integration of science-based behavioral interventions with evidence-based informational technologies. This work has been conducted in a variety of settings, including physician offices, substance abuse treatment programs, criminal justice settings, primary care settings, educational settings and via the Internet.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Forgiveness and Addiction: Addressing Resentment, Guilt, and Shame in Recovery (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning the skills that can facilitate the implementation of forgiveness in clinical practice, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that many see addiction as fundamentally a disease of the brain. Although clearly brain structures and functions are significantly involved in addictions, their impact not only involves the individual but the systems the surrounds those who are addicted. Family, friends, co-workers, and neighborhood, all are impacted by individuals with addictions, as they in return affect the individuals suffering from addiction. Frequently, feelings of anger, shame, guilt, resentment, and rejection, are present in both the patient and those surrounding the patient. 

    Usually, these feelings are in response to real or perceived transgressions or offenses by one or both parties, and it is not uncommon that trauma and guilt present continued stress which can interfere with recovery.  1 The concept of forgiveness can be a powerful tool to help patients address the injury and trauma that they have done or received by others. Shame, defined as a “flawed self, often accompanied by feelings of worthlessness and powerlessness” is associated with negative feelings and poorer recovery. In contrast, guilt, that focuses more on the behavior not necessarily reflected as the total self, is more amenable to forgiveness.2 Forgiveness as a disposition to where the use negative emotions for oneself or others can be important for many to achieve or sustain recovery.34 The Twelve-step facilitation model can be integrated, especially focusing on steps four through nine, as other models like CBT and ACT are able to use the concept of forgiveness in effective ways. The workshop will provide basic theoretical and clinical underpinnings, use case presentations, interactive discussions, to provide skills that can facilitate the implementation of forgiveness in clinical practice.” Addiction is more than a disease and involves more than the brain: it is a systemic behavioral disorder.”5

    Richard F. Camino-Gaztambide

    MD, MA

    Dr. Richard Camino is an associate professor of Psychiatry and Health Behavior and training director of the general psychiatric residency program at the Medical College of Georgia. Previously, Dr. Camino served as clerkship director and Associate Dean for Diversity and Inclusion at Mercer University. After finishing his Bachelor in Pharmaceutical Sciences from the University of Puerto Rico he graduated from the Universidad Central del Caribe School of Medicine in Puerto Rico. He completed his general psychiatry and child fellowship at the University Of Puerto Rico School Of Medicine. Additionally, Dr. Camino obtained a Masters in Arts in Theology from the University of Notre Dame. He holds board certification in general psychiatry, addiction psychiatry, and child and adolescent psychiatry. He has been active in the American Academy of Child and Adolescent Psychiatry, especially with their Religion and Spirituality Committee, where he is co-chair of the committee. 

    Dr. Camino practiced for 17 years in Puerto Rico and was recognized by his peers for 10 consecutive years to the “Doctor Choice Awards” given annually by a Buena Vida Health magazine. As an educator, he has given presentations in Buenos Aires, Medellin, Havana, Caracas, and Santo Domingo. His interests have been in education, cultural psychiatry, religion and spirituality in clinical practice, ADHD in children and adults (where he has done research), and addiction disorders.

    Eunice Malave de Leon

    MSW, EdD

    Eunice Malavé de León is a clinical social worker licensed to practice in several states. She holds a doctorate in education and is co-author in book chapters in several professional publications in family therapy and telemental health. She has extensive experience in cases of child sexual abuse, treating women from domestic violence, reconstituted families and families in underserved populations. Specializes in the management of family dynamics, works with adolescents, adults and the geriatric population. 

    Brett Daniel Kaylor

    DO

    No Bio available

    Jonathan Ek

    MD

    No bio available

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • The Success of ASAM’s CONTINUUM – Large System Adventures in Innovation (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about ASAM's Criteria from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about ASAM's criteria from the foremost experts in the field. 

    The ASAM Criteria decision rules are complex, leading to unauthorized, unvalidated attempts at abridgement. Eventually, the U.S. funded a standardized implementation: CONTINUUM™. Large county/state systems report a rapid learning curve and 60-minute average duration. The 10-minute CO-Triage™ provisionally determines the initial level-of-care referral. Piloting in Massachusetts (N=3,600) found good level-of-care distributions, conformity with ASAM’s principles, and provider/patient acceptance. Successful large system pilots have expanded public sector use in Massachusetts, Los Angeles and California’s prison system. In 2017, Los Angeles County (population: 10.1 million) signed a 10-year contract with ASAM for 1,500 clinicians to routinely use CONTINUUM and CO-Triage. A 25 year-long dream, this progress now demands serious new efforts by ASAM members, leaders and researchers.

    Learning Objectives: 

    • Upon completion, participant will be able to understand the evidence-base underlying the ASAM Criteria CONTINUUM™ system.
    • Upon completion, participant will be able to explain the purpose, clinical and system application of CO-Triage™ and CONTINUUM to decision makers.
    • Upon completion, participant will be able to participate in local and ASAM-wide planning and design enhancement to further the development of the CONTINUUM system.

    David R. Gasfriend

    MD, DFASAM

    "In his 25 years at Harvard Medical School, Dr. Gastfriend directed the Addiction Research Program at Massachusetts General Hospital and founded the MGH-McLean Addiction Psychiatry Fellowship. His research operationalized and validated ASAM’s Criteria, contributing to their endorsement by most U.S. states, the VA and the Department of Defense. These NIDA- and NIAAA-funded studies led to CONTINUUM - the ASAM Criteria Decision Engine(TM), developed with the support of the U.S. Substance Abuse and Mental Health Services Administration for nationwide release.

    From 2004-2013, Dr. Gastfriend was Vice President at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for alcohol and opioid dependence and conducted clinical, criminal justice, and health economic research in addiction.
    In 2014-2015 he was CEO of the Treatment Research Institute (TRI), the Philadelphia-based international research and policy center. He continues as Scientific Advisor, providing guidance to its researchers on projects such as the Addiction Severity Index and the Kennedy Foundation Parity Monitoring Project.

    In 2016, he co-founded, with his son, Eric Gastfriend MBA, DynamiCare Health(TM), to provide a nationally scalable, standardized, low-cost smartphone implementation for contingency management and foster wide-scale adoption of this evidence-based approach to incentivizing healthy recovery behaviors.

    NIDA granted him a Mid-Career Investigator Award for Patient-Oriented Research in 2000. In 2007, he received the Boston Business Journal's “Champion in Health Care – Innovator Award”. He is currently Principal Investigator on the $13 million PCORI-funded PATH Study of integrated addiction and primary care. He received ASAM's 2012 McGovern Award and Lecture for contributions to addiction treatment and society. Among his 150 scientific publications are ""The ASAM Criteria"" and ""Addiction Treatment Matching"". He has advised the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S. on alcohol and drug addiction treatment. "

    David Mee-Lee

    MD, FASAM

    David Mee-Lee, M.D. is a board-certified psychiatrist, and is certified by the American Board of Addiction Medicine (ABAM). Based in Davis, California, he trains and consults both nationally and internationally.  Dr. Mee-Lee is Chief Editor of the American Society of Addiction Medicine's (ASAM) Criteria for the Treatment of Addictive, Substance-Related, and Co-Occurring Conditions and is President of DML Training and Consulting. He is co-founder of the Institute for Wellness Education. Dr. Mee-Lee has forty years of experience in person centered treatment and program development for people with co-occurring mental health and substance use conditions.

    Paul H. Earley

    MD, DFASAM

    Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards. 

    Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.

    He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.

    Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.

    Gary Tsai

    MD, FASAM, FAPA

    Gary Tsai, M.D. is board certified in both general adult psychiatry and addiction medicine, and is the Medical Director and Science Officer of the Substance Abuse Prevention and Control, a division of the Los Angeles County Department of Public Health. In this role, he is responsible for providing clinical leadership to oversee substance use disorder (SUD) research, epidemiology and evaluation, as well as a full spectrum of SUD prevention, treatment, and recovery support services for the 10 million residents of Los Angeles County. He continues clinical practice at Cedars-Sinai Medical Center, and is a member of the Advisory Board of the Treatment Advocacy Center and Partners for StrongMinds, a former APA / SAMHSA Minority Fellow, and is active in the LPS Reform Task Force. 

    Having experienced the stigma and criminalization that often accompanies serious mental illness as the son of a mother with schizophrenia, Dr. Tsai is a passionate advocate for improving our behavioral health systems. In his pursuit of meaningful change, Dr. Tsai is also the founder of Forgotten Films, a film production company focusing on social issue projects, specializing in behavioral health. Its first film, "Voices," premiered on public television in May 2015 for Mental Health Awareness Month and was awarded a 2016 SAMHSA Voice Award, Honorable Mention.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • National Perspectives Plenary (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while listening to this conference recording from innovators shaping the field of addiction medicine at the national level at The ASAM 49th Annual Conference (2018). This session was made available free of charge by ASAM until 11/16/18.

    (1.0 CME) In this conference recording from the 2018 Annual Conference, connect with the innovators shaping the field at the national level. ASAM President Kelly J. Clark, MD, MBA, DFASAM, moderates an informal conversation with representatives from NIAAA, NIDA, and the CDC. The conversation includes questions on emerging issues and advances in addiction medicine, increasing the addiction medicine workforce, and improving the quality of care for patients.

    George F. Koob

    PhD

    George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

    Wilson Compton

    MD, MPE

    Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

    Debbie Dowell

    MD, MPH

    Debbie Dowell is Senior Medical Advisor/Chief Medical Officer for the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC), CDR in the US Public Health Service, and was the lead author of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. She previously led CDC’s Prescription Drug Overdose Team and served as advisor to New York City’s Health Commissioner. Dr. Dowell completed residency and chief residency in Primary Care Internal Medicine at the NYU School of Medicine, where she later joined the faculty as a clinical assistant professor. Dr. Dowell is Board Certified in Internal Medicine and practiced medicine at a community health center in New York City.

    She has conducted research on quality and safety in medical care, on the effects of clinical guidelines, and on the effectiveness of interventions to prevent opioid overdose, including Prescription Drug Monitoring Programs and academic detailing. She received her BA and MD from Columbia University, her MPH from the Johns Hopkins Bloomberg School of Public Health, and is a graduate of CDC’s Epidemic Intelligence Service (EIS).

    Kelly Clark (Moderator)

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • The ASAM Pain & Addiction: Common Threads XIX 2018 (8 CME)

    Contains 10 Product(s)

    Participants will learn clinical best practices and new research developments for treating patients with pain and addiction and how to begin to integrate these techniques into their own practices.

    OVERVIEW
    The ASAM Pain & Addiction: Common Threads Course is one of ASAM’s longest running and most popular courses. This course is designed to develop learners’ clinical skills and improve treatment of patients who fall somewhere in the gray area around pain and addiction. This course is designed for those in the addiction medicine field who already have some experience with pain and addiction.  

    This year’s course will address some of the most common barriers and challenges standing in the way of effective treatment and provide learners with skills or resources to immediately use in their practices. Presenters will address challenges such as appropriately assessing, diagnosing or treating patients (particularly those with psychiatric co-morbidities). Inaccurate diagnosis or referral can hinder treatment progress and impact patient trust in their health care providers. Presenters will also address complex, challenging patient cases such as patients on high doses of opioids or sedatives, patients with nicotine dependence, special patient populations, and many others. Lastly, presenters will review components of strong integrated practice settings and provide resources for learners to use in their own clinical practices. Many presentations will have a non-didactive component allowing participants to either self-reflect, review challenging cases, or engage with the presenters.

    LEARNING OBJECTIVES

    Upon completion, participants should be able to: 
    1. Distinguish between physiological dependence, substance use disorder, misuse, tolerance, and nonadherence in the context of pain.
    2. Use physical exams, functional assessments, screening tools, collateral information, and other tools in a clinical setting.
    3. Describe the interaction between pain, pain medication, addiction, and the patient’s emotional or psychological state. 
    4. Make appropriate treatment decisions for patients with pain, addiction, and psychiatric comorbidities.
    5. Explain the impacts of nicotine on pain treatment and develop methods for addressing nicotine use with patients.
    6. Manage the complex treatment needs of pregnant populations with pain and/or addiction.
    7. Direct or implement the medical management of withdrawal from opioids and other drugs.
    8. Evaluate the recent literature on benefits and limitations medication assisted treatment.
    9. Assess various practice models and create a plan for developing an integrated pain and addiction practice.

    This course is aimed toward addiction medicine specialists who treat patients with chronic pain and/or substance use disorders. Healthcare providers from other specialties who are interested in treating patients with chronic pain and addiction are also encouraged to attend.

    Upon completion, participants should be able to:

    1. Distinguish between physiological dependence, substance use disorder, misuse, tolerance, and nonadherence in the context of pain.
    2. Use physical exams, functional assessments, screening tools, collateral information, and other tools in a clinical setting.
    3. Describe the interaction between pain, pain medication, addiction, and the patient’s emotional or psychological state.
    4. Make appropriate treatment decisions for patients with pain, addiction, and psychiatric comorbidities.
    5. Explain the impacts of nicotine on pain treatment and develop methods for addressing nicotine use with patients.
    6. Manage the complex treatment needs of pregnant populations with pain and/or addiction.
    7. Direct or implement the medical management of withdrawal from opioids and other drugs.
    8. Evaluate the recent literature on benefits and limitations medication assisted treatment.
    9. Assess various practice models and create a plan for developing an integrated pain and addiction practice.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Move from Good to Great Presentations: Audience Aboard, Not Bored (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to enhance your presentation skills from this conference recording from The ASAM 49th Annual Conference (2018). This session was made available free of charge by the ASAM Medical Education Council until 11/16/18.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about how great presentations are the result of knowledge, skills, and resources that can be applied in any type of educational setting. This workshop will feature brief didactic information to enhance knowledge with tips on how to master stage presence, gain and hold audience attention, avoid distracting mannerisms and movements, and manage difficult audiences. 

    • The "rule of three" and elements that characterize an effective presentation will be described: tell 'em what you're going to tell 'em, tell 'em, tell 'em what you told them. 
    • Effective vs. ineffective slides will be illustrated, and the incorporation of other visual resources to motivate audience learning will be highlighted. 
    • The workshop will conclude with the audience members forming dyads, wherein each member will make a brief presentation in their area of expertise to the other, who will, in turn, provide feedback. 
    • As a concluding activity, two to three volunteers will be asked to make their presentation for the entire audience, and a group discussion with feedback will be led by the audience and leaders. 

    The session incorporates humor, which not only makes the workshop a fun experience, but also eases any "jitters" and apprehension among the audience members. Residents and fellows might especially benefit from this workshop, but anyone who wants to move from making good presentations to great presentations will find this workshop to be of value.

    Marcia Jackson

    PhD

    Dr. Marcia Jackson is President of CME by Design, a consulting group that provides the full range of instructional design services in the field of continuing medical education. Dr. Jackson served as division vice president and senior advisor for education at the American College of Cardiology from 1992-2007. She is a past President of the Alliance for Continuing Medical Education, a past member of the National Task Force on CME Provider/Industry Collaboration, and current chair of the Medscape Education Advisory Board, She is a recipient of the ACCME Robert Razskowski Award and the Alliance for CME Distinguished Service Award.  She has been an ASAM consultant since 2013.

    Mike Monahan

    MEd, RN

    Mike Monahan MEd, RN  President, Healthcare Resources Associates.  Mike provides performance improvement coaching, consulting and training serving the learning and development needs of individuals, teams, and organizations primarily in healthcare.  He has developed a particular interest in the needs of leaders facing the personal and professional challenges of today’s workplace.  He has been focusing on helping teams and individuals improve measurable performance and tend to the human side of work relationships.  Mike serves as a faculty development consultant for the American College of Cardiology and Mayo.  Mike is a frequent speaker at professional conferences and has published in journals as well as co-authoring several books.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Addiction Medicine Fellowships – Welcome to the New Era of ACGME (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™, while learning from experts in Addiction Medicine Fellow education, presenting the latest details on what is needed to design a fellowship that can successfully join the ranks of ACCME training programs, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn how this year will mark the historic debut of the first addiction medicine fellowship programs to operate under the flag of the Accreditation Council for Graduate Medical Education (ACGME). As this workshop takes place, the inaugural period of ACGME application submissions will have just started, based on policies and an application form that were finalized only two months ago. This workshop, therefore, is a unique and timely opportunity to learn the latest details on what is needed to design a fellowship that can successfully join the ranks of ACGME training programs. To date, nearly 50 fellowships have been started under the auspices of The Addiction Medicine Foundation (TAMF), and many of those are now in the first round of applicants for ACGME accreditation. At least another 75-80 new fellowships must be developed and accredited by 2025 to meet the projected need for addiction medicine physicians. This workshop, therefore, is designed for those addiction medicine champions interested in leading new fellowships, as well as for those from existing TAMF-accredited programs that are preparing for the transition to ACGME. 

    Presenters will include four addiction medicine educators who are leaders in TAMF and the Addiction Medicine Fellowship Directors Association (AMFDA), and who are also among those now drafting ACGME applications for their own fellowships. 

    Utilizing an interactive format of case study demonstration and dialogue, they will guide participants in planning strategies to design programs that are feasible within their home institutions and responsive to ACGME requirements. Breakout sessions will then enable participants to work in small groups on an actual ACGME application form, with presenters circulating to assist them in designing fellowship rotations that will build knowledge and skills in the core competencies of addiction medicine. Participants will then reassemble for a guided discussion to identify promising approaches that emerged in the application exercise, as well as to find solutions to any potential barriers that were encountered. At the workshop’s conclusion, arrangements will be made with interested participants for ongoing technical assistance from TAMF and AMFDA.

    Lon R. Hays

    MD, MBA, DFAPA, DFASAM

    Lon Roberts Hays, M.D., M.B.A. graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry where he has served as Chair from 1998 to 2018, and is director of the Addiction Medicine Fellowship.  In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified by the American Board of Addiction Medicine and has Added Qualifications in both Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School of Business in May 2001.  Dr. Hays is a Co-investigator on numerous grants involving drugs of abuse.  He is the Director of Area V of the American Academy of Addiction Psychiatry, President of the Addiction MedicineFoundation, a Distinguished Fellow of the American Psychiatric Association, and an elected member and Fellow of the American College of Psychiatrists."

    Randall Brown

    MD, PhD, DFASAM

    Dr. Brown is on the Board of Directors of The Addiction Medicine Foundation and is President-Elect of the Addiction Medicine Fellowship Directors Association. He is Board Certified in Family Medicine and Addiction Medicine. He has been heavily involved in fellowship development at the program for which he was the founding Director at the University of Wisconsin School of Medicine and Public Health, as well as at the national level. He serves as a consulting physician in addiction medicine at UW Hospital (where he is the Director of the Center for Addictive Disorders), William S. Middleton Memorial Veterans Hospital, the UW Hospital HIV/AIDS Clinic, and at Access Community Health Centers (a network of Federally Qualified Health Centers). Dr. Brown is also the Director of the UW SMPH fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin. Dr. Brown holds a PhD in Population Health Sciences from the University of Wisconsin.

    Timothy K. Brennan

    MD, MPH, FASAM

    Timothy Brennan, MD, MPH, FASAM is an Addiction Medicine physician and Pediatrician. He is the Director of the Addiction Institute at Mount Sinai West and St. Luke's Hospitals in New York City and the Vice President for Medical and Academic Affairs at The Addiction Medicine Foundation. He is also the Director of the Fellowship in Addiction Medicine at the Icahn School of Medicine at Mount Sinai. He completed a Fellowship in Addiction Medicine at the Addiction Institute of New York, a Fellowship in Medical Ethics at Harvard Medical School, a Residency in Pediatrics at Weill Cornell Medical College / New York Presbyterian Hospital, and an Internship in Internal Medicine at Georgetown University Hospital. He is the Co-Editor of Essentials of Addiction Medicine and Board Certified in Addiction Medicine and Pediatrics.

    Jeanette M. Tetrault

    MD, FACP, FASAM

    Dr. Tetrault’s scholarly work focuses on care of patients with addicition and the medical co-morbidities associated with substance use, mainly HIV and Hepatitis C. She is a diplomate of the American Board of Addiction Medicine. Dr. Tetrault is a physician providing primary care and buprenorphine/naloxone treatment at the Central Medical Unit of the APT Foundation, a multi-specialty addiction treatment facility, and is an attending physician at Yale New Haven Hospital (YNHH). She is the co-director of the Addiction Recovery Clinic in the Adult Primary Care Clinic at the St. Raphael's Campus of YNHH, which serves both a clinical care and a teaching mission. She was selected as a Macy Foundation Faculty Scholar in 2017. She is the Program Director for the Yale Addiction Medicine Fellowship Program and serves on the Board of Directors for The Addiction Medicine Foundation and the Addiction Medicine Fellowship Directors Association. She is a past-president of the New England Region of SGIM and co-chair of the Alcohol, Tobacco and Other Drug Use Interest Group for SGIM.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Becoming Certified in Addiction Medicine through ABPM (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about Practice Pathways and Fellowships leading to board certified in Addiction Medicine, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will discover that in the spring of 2017, ABPM offered physicians who are certified by a Member Board of the American Board of Medical Specialties (ABMS) the opportunity to apply and become certified in the subspecialty of Addiction Medicine. Marie A. Krousel-Wood, MD, MPH, ABPM Board Chair and Michael Weaver, MD, FASAM, Addiction Medicine Subboard Chair, will review the requirements and various pathways, i.e., Practice Pathway and Fellowship, available for physicians to apply for eligibility to sit for the Addiction Medicine subspecialty exam. Information on the timeline for the 2018 application cycle, dates for the examination period, and fee schedule will also be made available. Ample time will be provided for questions from the attendees. 

    For more information visit the ABPM website at www.theabpm.org.

    Christopher J. Ondrula

    JD

    Christopher J. Ondrula, is the Executive Director of the American Board of Preventative Medicine (ABMS).  Prior to joining ABMS in 2015, Mr. Ondrula served as the Chief Executive Officer and Director at Heartland Food Corporation, and the former Chief Operating Officer and General Counsel for Spence Group Services.

    A graduate of Miami University in Oxford, Ohio, Mr. Ondrula received his Juris Doctorate from Valparaiso University School of Law. Initially practicing in Chicago area law firms where his practice
    focused on the defense of medical malpractice claims and product liability litigation, he later joined the Arena Football League as its Assistant General Counsel.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Drug Testing: Principles and Biological Matrices in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The consensus document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    Michael M. Miller

    MD, LFAPA, DFASAM

    Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.

    Learning Objectives: 
    -Describe the principles of drug testing in the assessment and monitoring of patients with, or at risk for, addiction 
    -Discuss the benefits and liabilities of the different biological matrices relative to their roles in drug testing 
    -Highlight the consensus document's recommendations and discuss their use in clinical practice

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Speaker Disclosure

    Name: Michael M. Miller, MD, DFASAM

    Nature of Relevant Financial Relationship

    Category

    Organization

    Type of Relationship

    Consultant

    World Meds

    Modest ($10,000 or less)

    Consultant

    BDSI

    Modest ($10,000 or less)

    Consultant

    Braeburn

    Modest ($10,000 or less)

    Consultant

    Purdue Pharma

    Modest ($10,000 or less)

    Consultant

    WPS

    Modest ($10,000 or less)

    Speaker/Speaker’s Bureau

    BDSI

    Modest ($10,000 or less)


    ASAM CME Committee and Reviewers Disclosure Listing

    NameCommercial InterestWhat was received?For what role?
    Catherine Friedman, MD, FAPA, FASAM, ChairNone  
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
    None   
    Noel Ilogu, MD, MRCP, DFASAMNone  
    Hebert L. Malinoff, MD, FACP, DFASAMNone  
    Edwin A. Salsitz, MD, DFASAMNone  
    John C. Tanner, DO, DABAM, DFASAM, CCFC, MROIndivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker